Human immunodeficiency virus 1 (HIV-1) envelope-dependent cell–cell fusion modulation by HIV-positive sera is related to disease progression

References

1. Allaway G. P., Ryder A. M., Beaudry G. A., Maddon P. J. 1993; Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41. AIDS Res Hum Retroviruses 9:581–587 [CrossRef]
   [Google Scholar]
2. Amendola A., Gougeon M. L., Poccia F., Bondurand A., Fesus L., Piacentini M. 1996; Induction of “tissue” transglutaminase in HIV patogenesis: evidence for high rate apoptosis of CD4⁺ T lymphocytes and accessory cells in lymphoid tissues. Proc Natl Acad Sci U S A 93:11057–11062 [CrossRef]
   [Google Scholar]
3. Asherson R. A., Shoenfeld V. 2003; Human immunodeficiency virus infection, antiphospholipid antibodies, and the antiphospholipid syndrome. J Rheumatol 30:214–219
   [Google Scholar]
4. Blaak H., van't Wout A. B., Brouwer M., Hooibrink B., Hovenkamp E., Schuitemaker H. 2000; In vivo HIV-1 infection of CD45RA⁺CD4⁺ T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4⁺ T cell decline. Proc Natl Acad Sci U S A 97:1269–1274 [CrossRef]
   [Google Scholar]
5. Budka H. 1986; Multinucleated giant cells in brain: a hallmark of the acquired immune deficiency syndrome (AIDS). Acta Neuropathol 69:253–258 [CrossRef]
   [Google Scholar]
6. Cao J., Park I. W., Cooper A., Sodroski J. 1996; Molecular determinants of acute single-cell lysis by human immunodeficiency virus type 1. J Virol 70:1340–1354
   [Google Scholar]
7. Castedo M., Roumier T., Blanco J. 18 other authors 2002; Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV-1 envelope. EMBO J 21:4070–4080 [CrossRef]
   [Google Scholar]
8. Castro K. G., Ward J. W., Slutsker L., Buehler J. W., Jaffe H. W., Berkelman R. L. 1993; Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbid Mortal Wkly Rep 41:1–19
   [Google Scholar]
9. Cecilia D., Kleeberger C., Muñoz A., Giorgi J. V., Zolla-Pazner S. 1999; A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects. J Infect Dis 179:1365–1374 [CrossRef]
   [Google Scholar]
10. Connor R. I., Ho D. D. 1994; Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. J Virol 68:4400–4408
    [Google Scholar]
11. Connor R. I., Mohri H., Cao Y., Ho D. D. 1993; Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. J Virol 67:1772–1777
    [Google Scholar]
12. Etemad-Moghadam B., Rhone D., Steenbeke T. 9 other authors 2001; Membrane-fusing capacity of the human immunodeficiency virus envelope proteins determines the efficiency of CD4⁺ T-cell depletion in macaques infected by a simian-human immunodeficiency virus. J Virol 75:5646–5655 [CrossRef]
    [Google Scholar]
13. Ferri K. F., Jacotot E., Blanco J. 8 other authors 2000; Apoptosis control in syncytia induced by the HIV type 1-envelope glycoprotein complex: role of mitochondria and caspases. J Exp Med 192:1081–1092 [CrossRef]
    [Google Scholar]
14. Frankel S. S., Wenig B. M., Burke A. P., Manan P., Thompson L. D., Abbondazo S. L., Nelson A. M., Pope M., Steinman R. M. 1996; Replication of HIV-1 in dendritic cell-derived syncytia at the mucosal surface of the adenoid. Science 272:115–117 [CrossRef]
    [Google Scholar]
15. Gudiño J. C., Soler C. 2000; Detección de virus subtipo B del HIV-1 mediante el análisis de restricción de amplicones de gag con la enzima Bst Xi (REA-PCR). Abstracts from the I Congreso Nacional de la Rama de Bioquímica y Biología Molecular de Virus de la Sociedad Mexicana de Bioquímica. Rev Biomed 11:135–154
    [Google Scholar]
16. Gummurulu S., Kinsey M. C., Emerman M. 2000; An in vitro rapid-turnover assay for human immunodeficiency virus type 1 replication selects for cell-to-cell spread of virus. J Virol 74:10882–10891 [CrossRef]
    [Google Scholar]
17. Gupta P., Balachandran R., Ho M., Enrico A., Rinaldo C. 1989; Cell-to-cell transmission of human immunodeficiency virus type 1 in the presence of azidothymidine and neutralizing antibody. J Virol 63:2361–2365
    [Google Scholar]
18. Hioe C. E., Bastiani L., Hildreth J. E., Zolla-Pazner S. 1998; Role of cellular adhesion molecules in HIV type 1 infection and their impact on virus neutralization. AIDS Res Hum Retroviruses 14:S247–S254
    [Google Scholar]
19. Huerta L., Lamoyi E., Báez-Saldaña A., Larralde C. 2002; Human immunodeficiency virus envelope-dependent cell-cell fusion: a quantitative fluorescence cytometric assay. Cytometry 47:100–106 [CrossRef]
    [Google Scholar]
20. Kilby J. M., Hopkins S., Venetta T. M. 12 other authors 1998; Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 4:1302–1307 [CrossRef]
    [Google Scholar]
21. Koenig S., Gendelman H. E., Orenstein J. M. 7 other authors 1986; Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 233:1089–1093 [CrossRef]
    [Google Scholar]
22. Laurent-Crawford A. G., Krust B., Muller S., Riviere Y., Rey-Cuille M. A., Bechet J. M., Montagnier L., Hovanessian A. G. 1991; The cytopathic effect of HIV is associated with apoptosis. Virology 185:829–839 [CrossRef]
    [Google Scholar]
23. Lazzarin A., Clotet B., Cooper D. 14 other authors 2003; Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 348:2186–2219 [CrossRef]
    [Google Scholar]
24. Lifson J. D., Feinberg M. B., Reyes G. R. 7 other authors 1986; Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein. Nature 323:725–728 [CrossRef]
    [Google Scholar]
25. McKeating J. A., Zhang Y. J., Arnold C., Frederiksson R., Fenyo E.-M., Balfe P. 1996; Chimeric viruses expressing primary envelope glycoproteins of human immunodeficiency virus type 1 show increased sensitivity to neutralization by human sera. Virology 220:450–460 [CrossRef]
    [Google Scholar]
26. Miedema F., Meyaard L., Koot M. 11 other authors 1994; Changing virus-host interactions in the course of HIV-1 infection. Immunol Rev 140:35–72 [CrossRef]
    [Google Scholar]
27. Montefiori D. C., Pantaleo G., Fink L. M., Zhou J. T., Zhou J. Y., Bilska M., Miralles G. D., Fauci A. S. 1996; Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long term nonprogressors. J Infect Dis 173:60–67 [CrossRef]
    [Google Scholar]
28. Muller C., Kukel S., Schneweis K. E., Bauer R. 1994; Anti-lymphocyte antibodies in plasma of HIV-1-infected patients preferentially react with MHC class II-negative T cells and are linked to antibodies against gp41. Clin Exp Immunol 97:367–372
    [Google Scholar]
29. Ngo-Giang-Huong N., Candotti D., Goubar A. 8 other authors 2001; HIV type 1-specific IgG2 antibodies: markers of helper T cell type 1 response and prognostic marker of long-term nonprogression. AIDS Res Hum Retroviruses 17:1435–1446 [CrossRef]
    [Google Scholar]
30. Pantaleo G., Demarest J. F., Vaccareza M., Graziosi C., Bansal G. P., Koenig S., Fauci A. S. 1995; Effect of anti-V3 antibodies on cell-free and cell-to-cell human immunodeficiency virus transmission. Eur J Immunol 25:226–231 [CrossRef]
    [Google Scholar]
31. Phillips D. M. 1994; The role of cell-to-cell transmission in HIV infection. AIDS 8:719–731
    [Google Scholar]
32. Pilgrim A. K., Pantaleo G., Cohen O. J., Fink L. M., Zhou J. Y., Zhou J. T., Bolognesi D. P., Fauci A. S., Montefiori D. C. 1997; Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis 176:924–932 [CrossRef]
    [Google Scholar]
33. Poignard P., Sabbe R., Picchio G. R., Wang M., Gulizia R. J., Katinger H., Parren P. W. H. I., Mosier D. E., Burton D. R. 1999; Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 10:431–438 [CrossRef]
    [Google Scholar]
34. Posner M. R., Hideshima T., Cannon T., Mukherjee M., Mayer K. H., Byrn R. A. 1991; An IgG human monoclonal antibody that reacts with HIV-1/gp120, inhibits virus binding to cells, and neutralizes infection. J Immunol 146:4325–4332
    [Google Scholar]
35. Robert-Guroff M., Goedert J. J., Naugle C. J., Jenning A. M., Blattner W. A., Gallo R. C. 1988; Spectrum of HIV-1 neutralizing antibodies in a cohort of homosexual men: results of a 6 year prospective study. AIDS Res Hum Retroviruses 4:343–350 [CrossRef]
    [Google Scholar]
36. Sato H., Orenstein J., Dimitrov D., Martin M. 1992; Cell-to-cell spread of HIV-1 occurs within minutes and may not involve the participation of virus particles. Virology 186:712–724 [CrossRef]
    [Google Scholar]
37. Sekigawa I., Groopmen J. E., Allan J. D., Ikeuchi K., Biberfield G., Takatsuki K., Byrn R. A. 1991; Characterization of autoantibodies to the CD4 molecule in human immunodeficiency virus infection. Clin Immunol Immunopathol 58:145–153 [CrossRef]
    [Google Scholar]
38. Sodroski J., Goh W. C., Rosen C., Campbell K., Haseltine W. A. 1986; Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity. Nature 322:470–474 [CrossRef]
    [Google Scholar]
39. Trkola A., Ketas T., Kewalramani V. N., Endorf F., Binley J. M., Katinger H. 1998; Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage. J Virol 72:1876–1885
    [Google Scholar]
40. WHO 2001 Monitoring the emergence of antiretroviral resistance. Report of a WHO consultation in collaboration with Instituto di Sanitá and the Internationl AIDS Society. WHO/CDS/CSR/DRS/2001.11 World Health Organization;
    [Google Scholar]
41. Zwick M. B., Wang M., Poignard P., Stiegler G., Katinger H., Burton D. R., Parren P. W. 2001; Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J Virol 75:12198–12208 [CrossRef]
    [Google Scholar]